BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29314222)

  • 1. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim NH; Lee T; Cho YK; Kim BI; Kim HJ
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1397-1406. PubMed ID: 29314222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Fehrenbach U; Auer TA; Gebauer B; Kloeckner R
    United European Gastroenterol J; 2022 Feb; 10(1):41-53. PubMed ID: 34918471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
    Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
    Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
    Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.
    Zhang Q; Wang Y; Zhang J; Zhang W; Gong J; Ma R
    Technol Cancer Res Treat; 2021; 20():15330338211060180. PubMed ID: 34855560
    [No Abstract]   [Full Text] [Related]  

  • 11. Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma - a case-control study.
    Kirstein MM; Voigtländer T; Schweitzer N; Gebel M; Hinrichs JB; Rodt T; Manns MP; Wacker F; Potthoff A; Vogel A
    Scand J Gastroenterol; 2017 Dec; 52(12):1398-1406. PubMed ID: 28847187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients.
    Zeeneldin AA; Salem SE; Tabashy RH; Ibrahim AA; Alieldin NH
    J Egypt Natl Canc Inst; 2013 Sep; 25(3):143-50. PubMed ID: 23932751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series.
    Terzi E; Terenzi L; Venerandi L; Croci L; Renzulli M; Mosconi C; Allegretti G; Granito A; Golfieri R; Bolondi L; Piscaglia F
    Dig Dis; 2014; 32(6):711-6. PubMed ID: 25376288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
    Yang Z; Zou R; Zheng Y; Qiu J; Shen J; Liao Y; Zhang Y; Wang C; Wang Y; Yuan Y; Li K; Zuo D; He W; Liu W; Li B; Yuan Y
    Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?
    Allard MA; Sebagh M; Ruiz A; Guettier C; Paule B; Vibert E; Cunha AS; Cherqui D; Samuel D; Bismuth H; Castaing D; Adam R
    J Hepatol; 2015 Jul; 63(1):83-92. PubMed ID: 25646884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.